Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

And although shares fell 35% from peak-to-trough, it became apparent that those who seek these weight-loss drugs also tend to ...

T he Senate confirmation hearings for noted conspiracy theorist and dead-animal enthusiast Robert F. Kennedy Jr. have finally ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...

During a Senate HELP Committee hearing, RFK Jr. stated that President Trump is dedicated to bringing drug manufacturing "back ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

A new study suggested that users of GLP-1 receptor agonist medications like Ozempic spend less money at the grocery store: what dietitians want you to know.

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 ...